The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
Introduction: Mechanisms of resistance to EGFR exon 20 insertion mutation active inhibitors have not been extensively studied in either robust preclinical models or patient-derived rebiopsy specimens. We sought to characterize on-target resistance mutations identified in EGFR exon 20 insertion-mutat...
Main Authors: | Ikei S. Kobayashi, MD, PhD, William Shaffer, MS, Hollis Viray, MD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001571 |
Similar Items
-
Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2021-03-01) -
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
by: Diego Enrico, MD, et al.
Published: (2023-02-01) -
The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01) -
EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
by: Pedro E.N.S. Vasconcelos, MS, et al.
Published: (2020-09-01) -
EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)